



Germany, November 5, 2024

Exyte successfully completes the acquisition of TTP Group – EXAMPLE TEST PDF

Exyte has successfully completed the acquisition of TTP Group ("TTP"). The transaction, announced in September 2024, has closed following the receipt of all required regulatory approvals. Exyte will combine TTP's operations with its own Biopharma and Life Sciences activities in Europe, aiming to establish an even stronger partnership with the rapidly growing European biotechnology and pharmaceutical sectors.

- Closing of transaction following the receipt of all required regulatory approvals
- TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industries
- Clients include blue-chip companies from biotech and pharma sectors across Europe
- Exyte CEO Büchele: "The acquisition of TTP brings additional engineering expertise, experience, and business opportunities to Exyte, particularly in the thriving European biopharma and life sciences markets."

"We will strengthen our presence in Europe's biotech and pharma sectors, offering clients comprehensive support from strategic planning to facility delivery."

Exyte CEO Büchele

TTP is a specialized and trusted partner for blue-chip clients in the biotech, pharma and chemical industries across Europe. The company, through its two operational brands 'Pharmaplan' and 'Triplan', covers the entire service spectrum from Engineering to Procurement, Construction

Management, and Validation.

Exyte will combine TTP's operations with its own Biopharma and Life Sciences activities in Europe, aiming to establish an even stronger partnership with the rapidly growing European biotechnology and pharmaceutical sectors. This acquisition further solidifies Exyte's position as a global player in the pharma market, enhancing its presence and capabilities in Europe.

Exyte CEO Dr. Wolfgang Büchele says, “This strategic move is an important step for Exyte on our 'Pathway to Ten' and aligns perfectly with our future agenda 'Next Level'. By combining TTP's engineering expertise with Exyte's project execution capabilities, we will strengthen our presence in Europe's biotech and pharma sectors, offering clients comprehensive support from strategic planning to facility delivery.”

Dr. Andreas Bonhoff, CEO of TTP Group, states, “TTP and Exyte share the ambition to offer innovative, sustainable solutions, and together, we will continue to expand in the growing market for pharmaceutical facilities. The combination of our strengths is a win for our clients and a positive step towards a successful future.”

Strategic expansion of Biopharma & Life Sciences

The Global Business Unit Biopharma and Life Sciences, led by President Ronan Donohue, is the second-largest segment of Exyte by sales. Revenue of Biopharma and Life Sciences reached €580 million in 2023. The order intake grew by 12 percent to €650 million. As part of the "Next Level" agenda, the segment's sales are expected to continue growing, with its share of total sales increasing further. In the medium term, Exyte's business segment Biopharma and Life Sciences plans to achieve more than €1.5 billion in sales. Donohue says, “The combination of TTP with our current European organization in the Biopharma and Life Science business segment is a key accelerator for the growth of the Global Business Unit.”

Public Relations Manager

Samy Abdel Aal

For any further question or should you require additional information please feel free to contact:

Phone: +49 711 88044696

Mobil: +49 172 840 33 01

samy.abdelaal@exyte.net

Please understand that our press office can only answer questions from journalists. Please refer to our general contact email for contacts on other matters.